Last reviewed · How we verify
LEO 90105 = calcipotriol + betamethasone dipropionate
LEO 90105 = calcipotriol + betamethasone dipropionate is a Topical combination therapy (vitamin D analog + corticosteroid) Small molecule drug developed by LEO Pharma. It is currently in Phase 3 development for Plaque psoriasis (topical treatment). Also known as: LEO 90105 = Dovobet/Daivobet/Taclonex.
LEO 90105 combines a vitamin D analog (calcipotriol) that regulates skin cell differentiation with a potent topical corticosteroid (betamethasone dipropionate) to reduce inflammation and abnormal keratinocyte proliferation in psoriasis.
LEO 90105 combines a vitamin D analog (calcipotriol) that regulates skin cell differentiation with a potent topical corticosteroid (betamethasone dipropionate) to reduce inflammation and abnormal keratinocyte proliferation in psoriasis. Used for Plaque psoriasis (topical treatment).
At a glance
| Generic name | LEO 90105 = calcipotriol + betamethasone dipropionate |
|---|---|
| Also known as | LEO 90105 = Dovobet/Daivobet/Taclonex |
| Sponsor | LEO Pharma |
| Drug class | Topical combination therapy (vitamin D analog + corticosteroid) |
| Target | Vitamin D receptor (VDR); glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Calcipotriol acts as a vitamin D3 receptor agonist, promoting normal differentiation and reducing proliferation of keratinocytes while modulating immune responses in the skin. Betamethasone dipropionate is a Class III corticosteroid that suppresses local inflammatory cytokines and immune cell infiltration. The combination provides synergistic anti-inflammatory and anti-proliferative effects for treating plaque psoriasis.
Approved indications
- Plaque psoriasis (topical treatment)
Common side effects
- Application site irritation
- Skin atrophy (with prolonged use)
- Folliculitis
- Pruritus
Key clinical trials
- LEO 90105 Ointment in Japanese Subjects With Psoriasis (PHASE3)
- The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LEO 90105 = calcipotriol + betamethasone dipropionate CI brief — competitive landscape report
- LEO 90105 = calcipotriol + betamethasone dipropionate updates RSS · CI watch RSS
- LEO Pharma portfolio CI
Frequently asked questions about LEO 90105 = calcipotriol + betamethasone dipropionate
What is LEO 90105 = calcipotriol + betamethasone dipropionate?
How does LEO 90105 = calcipotriol + betamethasone dipropionate work?
What is LEO 90105 = calcipotriol + betamethasone dipropionate used for?
Who makes LEO 90105 = calcipotriol + betamethasone dipropionate?
Is LEO 90105 = calcipotriol + betamethasone dipropionate also known as anything else?
What drug class is LEO 90105 = calcipotriol + betamethasone dipropionate in?
What development phase is LEO 90105 = calcipotriol + betamethasone dipropionate in?
What are the side effects of LEO 90105 = calcipotriol + betamethasone dipropionate?
What does LEO 90105 = calcipotriol + betamethasone dipropionate target?
Related
- Drug class: All Topical combination therapy (vitamin D analog + corticosteroid) drugs
- Target: All drugs targeting Vitamin D receptor (VDR); glucocorticoid receptor (GR)
- Manufacturer: LEO Pharma — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Plaque psoriasis (topical treatment)
- Also known as: LEO 90105 = Dovobet/Daivobet/Taclonex